Bayer (BAYN) Stock Rating Reaffirmed by Citigroup

Citigroup restated their buy rating on shares of Bayer (FRA:BAYN) in a report published on Thursday morning.

A number of other research analysts have also weighed in on BAYN. Warburg Research set a €121.00 ($144.05) price target on Bayer and gave the stock a neutral rating in a research note on Thursday. JPMorgan Chase & Co. set a €128.00 ($152.38) price target on Bayer and gave the stock a buy rating in a research note on Wednesday. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the stock a neutral rating in a research note on Wednesday, September 13th. Commerzbank set a €124.00 ($147.62) price target on Bayer and gave the stock a buy rating in a research note on Friday, September 15th. Finally, Jefferies Group set a €132.00 ($157.14) price objective on Bayer and gave the stock a buy rating in a report on Monday, September 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of €122.33 ($145.63).

Bayer (BAYN) opened at €104.86 ($124.83) on Thursday. Bayer has a 52 week low of €99.69 ($118.68) and a 52 week high of €123.82 ($147.40). The firm has a market capitalization of $86,730.00 and a price-to-earnings ratio of 28.11.

WARNING: “Bayer (BAYN) Stock Rating Reaffirmed by Citigroup” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thestockobserver.com/2018/01/14/bayer-bayn-stock-rating-reaffirmed-by-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply